Skip to main content
Premium Trial:

Request an Annual Quote

Devyser's Fetal Test Gains IVDR Certification

The story has been corrected. It previously incorrectly said that Devyser's aneuploidy test can be used to detect aneuploidy in fetal cells circulating in maternal blood.

NEW YORK — Swedish diagnostics company Devyser said on Monday that its quality management system and fetal diagnostics product have been certified under Europe's new In Vitro Diagnostic Regulation.

Europe recently transitioned to the new regulation, which requires most molecular tests to be certified by a designated organization, called a notified body. Munich, Germany-based TÜV Süd issued Devyser's certificate, the Stockholm-based company said.

CEO Fredrik Alpsten said that Devyser has worked for years to meet IVDR regulations, and that the certification "shows that Devyser has a development and quality organization that can compete with the best in Europe."

Devyser develops and markets genetic testing kits used for advanced DNA testting in the hereditary disease, oncology, and transplant fields.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.